Person:
Abraham, Jacob

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Abraham

First Name

Jacob

Name

Abraham, Jacob
Author's Publications: search.filters.isAuthorOfPublication.8cdbf6b6-7086-4453-9095-58263a88b3e0

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Lineage of origin in rhabdomyosarcoma informs pharmacological response
    (Cold Spring Harbor Laboratory Press, 2014) Abraham, Jacob; Nunez-Alvarez, Y.; Hettmer, Simone; Carrio, E.; Chen, Hung-I Harry; Nishijo, K.; Huang, Elaine; Prajapati, Suresh I.; Walker, Robert L.; Davis, Sean; Rebeles, Jennifer; Wiebush, Hunter; McCleish, Amanda T.; Hampton, Sheila T.; Bjornson, Christopher R.R.; Brack, Andrew S; Wagers, Amy; Rando, Thomas A.; Capecchi, Mario R.; Marini, Frank C.; Ehler, Benjamin R.; Zarzabal, Lee Ann; Goros, Martin W.; Michalek, Joel E.; Meltzer, Paul S.; Langenau, David; LeGallo, Robin D.; Mansoor, Asif Imran; Chen, Yidong; Suelves, Monica; Rubin, Brian P.; Keller, Charles
    Lineage or cell of origin of cancers is often unknown and thus is not a consideration in therapeutic approaches. Alveolar rhabdomyosarcoma (aRMS) is an aggressive childhood cancer for which the cell of origin remains debated. We used conditional genetic mouse models of aRMS to activate the pathognomonic Pax3:Foxo1 fusion oncogene and inactivate p53 in several stages of prenatal and postnatal muscle development. We reveal that lineage of origin significantly influences tumor histomorphology and sensitivity to targeted therapeutics. Furthermore, we uncovered differential transcriptional regulation of the Pax3:Foxo1 locus by tumor lineage of origin, which led us to identify the histone deacetylase inhibitor entinostat as a pharmacological agent for the potential conversion of Pax3:Foxo1-positive aRMS to a state akin to fusion-negative RMS through direct transcriptional suppression of Pax3:Foxo1.